ePrints

Rituximab for myasthenia gravis

Lookup NU author(s): Dr James Miller

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess:. the safety and efficacy, as assessed by the effect on disease severity or functional ability and the burden of alternative treatment, of rituximab (including biosimilar variants) for the treatment of myasthenia gravis in adults; and outcomes and adverse effects between different patient subgroups, and treatment strategies, in order to aid treatment choice for individuals, and to inform policymakers about those most likely to benefit.

Publication metadata

Author(s): Dodd KC, Clay FJ, Forbes A-M, Keh YS, Miller JAL, Sussman J, Lilleker JB

Publication type: Article

Publication status: Published

Journal: Cochrane Database of Systematic Reviews

Year: 2023

Volume: 2023

Issue: 4

Online publication date: 05/04/2023

Acceptance date: 02/04/2022

ISSN (electronic): 1469-493X

Publisher: John Wiley and Sons Ltd

URL: https://doi.org/10.1002/14651858.CD014574

DOI: 10.1002/14651858.CD014574

Altmetrics

Share